Cargando…

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ulahannan, Susanna V, Brahmer, Julie R
Formato:	Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082199/ https://www.ncbi.nlm.nih.gov/pubmed/21469981 http://dx.doi.org/10.3109/07357907.2011.554476

Ejemplares similares

The Efficacy of Combining Antiangiogenic Agents with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review and Meta-Analysis
por: Sheng, Jin, et al.
Publicado: (2015)

A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis
por: Li, Yimin, et al.
Publicado: (2020)

Advances in antiangiogenic treatment of small-cell lung cancer
por: Lu, Hongyang, et al.
Publicado: (2017)

Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR‐TKIs in advanced non‐small cell lung cancer: A systematic review and network meta‐analysis
por: Dai, Jiali, et al.
Publicado: (2023)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma
por: Vo, Kieuhoa T., et al.
Publicado: (2016)

Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
por: Yang, Yaning, et al.
Publicado: (2023)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
por: Ma, Ke, et al.
Publicado: (2023)

Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy
por: Wu, Yahua, et al.
Publicado: (2023)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
por: Xu, Yinghui, et al.
Publicado: (2022)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
por: Xu, Ziyi, et al.
Publicado: (2021)

Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)

Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects
por: Zhao, Xiaoliang, et al.
Publicado: (2016)

Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1(‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort
por: Xia, Ruolan, et al.
Publicado: (2023)

Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models
por: Shi, Shujing, et al.
Publicado: (2013)

Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer
por: Chen, Jin-Hua, et al.
Publicado: (2018)

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond
por: Gori, Bruno, et al.
Publicado: (2011)

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype
por: Larrayoz, Marta, et al.
Publicado: (2014)

Enhanced Anticancer Activity of Gemcitabine in Combination with Noscapine via Antiangiogenic and Apoptotic Pathway against Non-Small Cell Lung Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
por: Xuan, Tian-Tian, et al.
Publicado: (2022)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
por: Feng, Yu, et al.
Publicado: (2022)

Chemotherapy in non-small cell lung cancer: opportunities for advancement
por: Akhtari, Mani, et al.
Publicado: (2016)

Radiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer
por: Yang, Wen-Hui, et al.
Publicado: (2019)

Baseline tumour measurements predict survival in advanced non-small cell lung cancer
por: Gerber, D E, et al.
Publicado: (2013)

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer
por: Marrone, Kristen A., et al.
Publicado: (2018)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer
por: TAS, FARUK, et al.
Publicado: (2013)

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
por: Nishino, Mizuki, et al.
Publicado: (2012)

Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy
por: Rajora, Amit Kumar, et al.
Publicado: (2020)

Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis
por: Li, Jiaqi, et al.
Publicado: (2022)

Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Ma, Jie-Tao, et al.
Publicado: (2021)

VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review
por: Liu, Lian, et al.
Publicado: (2019)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Cui, Yu-jie, et al.
Publicado: (2021)

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
por: Liang, Hongge, et al.
Publicado: (2019)

Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
por: Russo, Francesca, et al.
Publicado: (2008)

Emerging therapeutic agents for advanced non-small cell lung cancer
por: Chen, Ruqin, et al.
Publicado: (2020)

Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)
por: Gridelli, Cesare, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2u7hmd0vgf70v7nh0fbvkjtic9